BIOPLUS-INTERPHEX KOREA 2025 Officially Opens Visitor Registration


Posted August 6, 2025 by RX-PRandMedia

Countdown Begins for Asia’s Defining Biopharma Business Platform

 
The momentum toward BIOPLUS-INTERPHEX KOREA 2025 (BIX 2025) has officially begun, with visitor registration opening July 10 for Asia's most influential biopharmaceutical exhibition and conference. Returning to COEX, Seoul from 15–17 October, BIX 2025 sets the stage for three dynamic days of scientific exchange, business development, and international collaboration in the life sciences sector.



BIX 2025 brings together professionals and decision-makers from across the global biopharma value chain. From cutting-edge therapies to next-generation manufacturing, the event presents a timely platform for exploring trends, building strategic partnerships, and accelerating innovation. This year’s edition promises a wider international presence, deeper content, and enhanced networking opportunities designed to support meaningful progress across the industry.



More than an exhibition, BIX 2025 is a gateway to discovery and influence. The event draws researchers, executives, regulators, and investors under one roof, providing an opportunity to explore emerging solutions in biotechnology, pharmaceuticals, bioprocessing, and more. Visitors can expect rich content across key industry segments – from drug discovery and clinical trials to biologics manufacturing, AI in healthcare, regulatory policy, and investment strategies.



Key Event Features

Exhibition Show Floor

Spanning biotechnology, diagnostics, drug delivery systems, manufacturing equipment, and bioprocessing solutions, the exhibition will showcase a comprehensive view of the global biopharma supply chain. Key exhibitors include industry leaders Samsung Bioepis, Merck, Sartorius, Thermo Fisher Scientific, STgen Bio, Samsung Biologics, Acro Biosystems, Almac, BD, Bora Biologics, IDBS, Lonza, West Pharmaceuticals, and Cytiva. Last year's show hosted over 300 companies and 9,000 visitors; 2025 is expected to surpass these figures, attracting participants from more than 30 countries.



Partnering Opportunities

The dedicated BIX Partnering Platform facilitates targeted business meetings between exhibitors, start-ups, investors, and global pharmaceutical companies. These sessions are curated to foster dialogue, unlock synergies, and help participants fast-track commercial engagement.



Conference Program

The multi-track conference brings together thought leaders from across academia, government, and industry to discuss everything from digital therapeutics to policy updates. This comprehensive program features 36 sessions and 130 distinguished speakers across two specialized tracks: Insight Sessions and Technical Sessions.

Under the 2025 theme "Innovation Blooms No Matter What," the conference delivers a carefully curated blend of keynote sessions, expert panels, and case-driven presentations designed to address real-world challenges facing the biomedical innovation landscape. The dual-track format ensures both strategic insights and technical deep-dives, catering to diverse professional needs while fostering cross-sector collaboration and knowledge exchange.

Attendees can expect actionable intelligence from industry pioneers, world-class research findings from leading academics, and forward-thinking policy perspectives from government leaders—all unified under a theme that celebrates resilience and breakthrough innovation in any environment.



Open Innovation

The Open Innovation Program at BIX KOREA's exhibition stage provides a strategic platform for emerging biopharmaceutical companies to present their latest products and breakthrough technologies. This dedicated showcase creates targeted networking opportunities between industry innovators, investors, and potential partners in a structured yet accessible environment.

The program is specifically designed to facilitate meaningful business connections and accelerate innovation partnerships within the biopharmaceutical ecosystem. Participating companies will have the opportunity to demonstrate their cutting-edge solutions while engaging directly with key stakeholders, fostering the collaborative relationships essential for advancing biomedical innovation.



Flexible Pass Options to Suit Every Visitor

This year’s ticketing structure has been thoughtfully designed to provide flexible access depending on a visitor’s professional goals. Pass types include:



All-Inclusive Pass: For industry leaders seeking full access to exhibition, conference, and VIP networking. Ideal for: CEOs, C-level executives, startup founders, and investors.

EE (Exhibition Executive) Pass: Focused on business matchmaking and high-level networking with exhibitors. Ideal for: Senior managers in business development, licensing, and distribution.

Standard Pass: For professionals looking to dive into the latest insights and tech trends. Ideal for: R&D, marketing, global business, clinical, and regulatory teams.

Entry Pass: Designed for exploring the exhibition and getting a broad industry overview. Ideal for: Academia, public institutions, and general industry professionals.



Visitors are encouraged to take advantage of early-bird pricing, with up to 50% off ticket packages for those who register by 31 August 2025. This limited-time offer provides a cost-effective way to experience the full breadth of the event, particularly for those seeking in-depth participation across partnering and conference activities. Register here.





Your Journey Starts Here

BIOPLUS-INTERPHEX KOREA 2025 is the definitive platform for anyone involved in the life sciences – from drug development and manufacturing to investment and government affairs. It is a space where ambition meets opportunity, and where today’s ideas are transformed into tomorrow’s impact.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse Content Requests
Contact Email [email protected]
Issued By RX Korea (Reed Exhibitions Korea Ltd.)
Country Korea, Republic of
Categories Medical
Tags bix2025
Last Updated August 6, 2025